文献速递中毒与环境急症心脑血管急症重症综合管理与镇静镇痛

大剂量胰岛素血糖正常疗法在毒素所致心脏毒性中的安全性

The safety of high-dose insulin euglycaemia therapy in toxin-induced cardiac toxicity.
PubMed 文献 · Clin Toxicol (Phila) · 2017-10-26
一句话结论22例毒素所致心脏毒性患者接受大剂量胰岛素血糖正常疗法,16例(73%)发生低血糖、18例(82%)发生低钾血症,但未见相关神经或心脏并发症。

这项来自两个临床毒理学单元的回顾性病例复习纳入22例接受大剂量胰岛素血糖正常疗法(HIE)的毒素所致心脏毒性患者,其中12例为β受体阻滞剂、6例为钙通道阻滞剂、3例为两者联合中毒。结果显示,尽管给予葡萄糖和电解质补充,16例(73%)仍发生低血糖(7例轻度2.5-3.4 mmol/L,9例重度<2.5 mmol/L),18例(82%)发生低钾血症(16例轻度2.5-3.4 mEq/L),但未出现低血糖相关神经效应或低钾血症相关心律失常,3例死亡。胰岛素剂量与低血糖或低钾血症严重程度、葡萄糖或钾补充量之间无明显关联;停用胰岛素后葡萄糖中位继续输注18小时,且该时长随HIE期间胰岛素输注速率和总量增加而延长。

要点

  • 22例毒素所致心脏毒性患者接受HIE,16例(73%)发生低血糖(<3.5 mmol/L或<63 mg/dl),其中9例为重度(<2.5 mmol/L或<45 mg/dl)。
  • 18例(82%)发生低钾血症(<3.5 mEq/L),16例为轻度(2.5-3.4 mEq/L),未出现相关心律失常。
  • 胰岛素剂量与低血糖或低钾血症严重程度、葡萄糖或钾补充量之间无明显关联。
  • 停用胰岛素后葡萄糖中位继续输注18小时,且输注时长随HIE期间胰岛素速率和总量增加而延长。
  • 22例中19例收缩压<80 mmHg,18例除HIE外还需正性肌力药物,3例死亡。

适用人群与场景

  • 来自两个临床毒理学单元的毒素所致心脏毒性患者,共22例(12例女性),中位年龄57岁(15-88岁)。
  • 中毒类型:12例β受体阻滞剂、6例钙通道阻滞剂、3例β受体阻滞剂与钙通道阻滞剂联合中毒。

处置流程与药物剂量

  • HIE中位胰岛素负荷剂量80 U(范围50-125 U),中位最大胰岛素输注速率150 U/h(范围38-1500 U/h)。
  • 中位葡萄糖输注速率37.5 g/h(范围4-75 g/h)。
  • 尽管给予葡萄糖和电解质补充,仍发生低血糖和低钾血症;停用胰岛素后葡萄糖中位继续输注18小时。

红旗征与不能漏的情况

  • 低血糖:16例(73%)发生,参考范围<3.5 mmol/L或<63 mg/dl;7例轻度(2.5-3.4 mmol/L或45-62 mg/dl),9例重度(<2.5 mmol/L或<45 mg/dl),未出现低血糖相关神经效应。
  • 低钾血症:18例(82%)发生(<3.5 mEq/L),16例轻度(2.5-3.4 mEq/L),未出现相关心律失常。
  • 血流动力学不稳定:19例收缩压<80 mmHg,18例除HIE外需正性肌力药物。

研究设计与关键结果

  • 回顾性病例复习,来自两个临床毒理学单元,共22例接受HIE的毒素所致心脏毒性患者。
  • 16例(73%)发生低血糖,18例(82%)发生低钾血症,3例死亡;未出现低血糖相关神经效应或低钾血症相关心律失常。
  • 胰岛素剂量与低血糖或低钾血症严重程度、葡萄糖或钾补充量之间无明显关联;胰岛素与葡萄糖给药量之间无明显关联。
  • 停用胰岛素后葡萄糖中位继续输注18小时,且该时长随HIE期间胰岛素输注速率和总量增加而延长。

证据类型、等级与局限

  • 证据类型:回顾性病例复习(两个临床毒理学单元)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,尽管HIE在毒素所致心脏毒性中有获益,但其对葡萄糖和电解质稳态造成显著干扰,不过未见明显并发症。
  • 作者认为,比较胰岛素给药量与不良反应或葡萄糖给药量未见关联,提示较高剂量胰岛素与不增加不良反应相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

CONTEXT: High-dose insulin euglycaemia (HIE) is recommended in the management of toxin-induced cardiac toxicity, with increasing insulin doses now being used. We aimed to investigate the safety of HIE in toxin-induced cardiac toxicity.

METHODS: This was a retrospective review of cases from two clinical toxicology units. Demographics, toxin(s) ingested, clinical effects, investigations (serum glucose, electrolytes), treatments (insulin, glucose, electrolyte replacement), length of stay (LOS) and outcomes were extracted from the patients' medical records. Associations between insulin and glucose/electrolyte homeostasis were explored by comparing insulin administration and glucose or electrolyte concentrations and replacement.

RESULTS: There were 22 patients (12 females), median age 57 years (15-88 years) treated with HIE. There were 12 beta-blocker, six calcium channel blocker and three combined beta-blocker and calcium channel blocker ingestions. A total of 19 patients had a systolic blood pressure <80mmHg and 18 patients required inotropes in addition to HIE. There were three deaths. Despite glucose and electrolyte replacement, 16 patients (73%) developed hypoglycaemia (Reference range [RR] < 3.5 mmol/L or <63 mg/dl). In 7 patients, hypoglycaemia was mild (2.5-3.4 mmol/L or 45-62 mg/dl) and in nine was severe (<2.5 mmol/L or <45 mg/dl). There were no neurological effects from hypoglycaemia. A total of 18 patients (82%) developed hypokalaemia (<3.5 mEq/L). In 16 patients, this was mild (2.5-3.4 mEq/L). There were no cardiac arrhythmias associated with this hypokalaemia. There was no apparent association between insulin dosing and severity of hypoglycaemia or hypokalaemia, or in glucose or potassium replacement. Median insulin loading dose was 80U (range 50-125 U) and the median maximum insulin infusion rate was 150 U/h (range 38-1500 U/h). Median glucose infusions rates were 37.5g/h (range 4-75g/h). There was no apparent association between insulin and glucose administration. Glucose was administered for a median of 18h after ceasing insulin. The duration of glucose administration after ceasing insulin increased with the rate and total insulin administered during HIE.

DISCUSSION: Despite the benefits of HIE in toxin-induced cardiac toxicity, it caused significant disruption to glucose and electrolyte homeostasis, although there were no apparent complications from this. There was no association by comparing the amount of insulin administered on adverse effects or glucose administered, suggesting higher doses of insulin are associated with no more adverse effects.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Page CB, Ryan NM, Isbister GK, et al. The safety of high-dose insulin euglycaemia therapy in toxin-induced cardiac toxicity. Clin Toxicol (Phila). 2017. PMID: 29069937. doi:10.1080/15563650.2017.1391391

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。